111 related articles for article (PubMed ID: 33391772)
1. Bronchoesophageal fistula formation after three courses of nivolumab for carcinoma of unknown primary with a subgroup of lung squamous cell carcinoma.
Nishiyama A; Sakaguchi H; Yanagimura N; Suzuki C; Otani S; Tanimoto A; Yamashita K; Takeuchi S; Ohtsubo K; Ikeda H; Yano S
Oxf Med Case Reports; 2020 Dec; 2020(12):omaa116. PubMed ID: 33391772
[TBL] [Abstract][Full Text] [Related]
2. Rare complication of bronchoesophageal fistula due to pulmonary mucormycosis after induction chemotherapy for acute myeloid leukemia: a case report.
Lee JH; Hyun JS; Kang DY; Lee HJ; Park SG
J Med Case Rep; 2016 Jul; 10():195. PubMed ID: 27423701
[TBL] [Abstract][Full Text] [Related]
3. Severe eosinophilia and subsequent dermatologic immune-related adverse event with squamous cell carcinoma antigen elevation induced by nivolumab and ipilimumab.
Matsumoto T; Kaneko A; Kusakabe Y; Nakayama E; Tanaka A; Yamamoto N; Aihara K; Yamaoka S; Mishima M
Respirol Case Rep; 2022 Oct; 10(10):e01037. PubMed ID: 36176718
[TBL] [Abstract][Full Text] [Related]
4. The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
Chai QQ; Du JY; Zhu J; Wu B
Front Pharmacol; 2019; 10():1260. PubMed ID: 31708783
[No Abstract] [Full Text] [Related]
5. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
6. Development of Severe Heart Failure in a Patient with Squamous Non-small-cell Lung Cancer During Nivolumab Treatment.
Samejima Y; Iuchi A; Kanai T; Noda Y; Nasu S; Tanaka A; Morishita N; Suzuki H; Okamoto N; Harada H; Ezumi A; Ueda K; Kawahara K; Hirashima T
Intern Med; 2020 Aug; 59(16):2003-2008. PubMed ID: 32448839
[TBL] [Abstract][Full Text] [Related]
7. Esophageal bypass surgery as a definitive repair of recurrent acquired benign bronchoesophageal fistula.
Vachtenheim J; Lischke R
J Cardiothorac Surg; 2019 Apr; 14(1):73. PubMed ID: 30971283
[TBL] [Abstract][Full Text] [Related]
8. A Malignant Connection: Bronchoesophageal-Pleural Fistula in an Elderly Farmer.
Gaine S; Danish H; Binalialsharabi W; Fennessy S; Morcos A; Rogan M
Cureus; 2022 Aug; 14(8):e27966. PubMed ID: 36134059
[TBL] [Abstract][Full Text] [Related]
9. [Bronchoesophageal fistula in a patient with untreated malignant lymphoma].
Uenogawa K; Hatta Y; Oshiro S; Hagikura K; Takahashi N; Kura Y; Yamazaki T; Akashiba T; Sawada U; Horie T
Rinsho Ketsueki; 2005 Sep; 46(9):1071-3. PubMed ID: 16440767
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of Advanced or Postoperative Recurrent Non-small Lung Cancer Cases Treated with Nivolumab].
Ichiki Y; Iwanami T; Kakizoe K; Hamatsu T; Suehiro T; Yoneda K; Tanaka F; Sugimachi K
J UOEH; 2017; 39(4):291-297. PubMed ID: 29249742
[TBL] [Abstract][Full Text] [Related]
11. Immune thrombocytopenia induced by nivolumab in a patient with non-small cell lung cancer.
Mori H; Sakai C; Iwai M; Sasaki Y; Gomyo T; Toyoshi S; Kaito D; Yanase K; Ito F; Endo J; Funaguchi N; Ohno Y; Minatoguchi S
Respir Med Case Rep; 2019; 28():100871. PubMed ID: 31198679
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report.
Koda R; Watanabe H; Tsuchida M; Iino N; Suzuki K; Hasegawa G; Imai N; Narita I
BMC Nephrol; 2018 Feb; 19(1):48. PubMed ID: 29486725
[TBL] [Abstract][Full Text] [Related]
13. Double congenital bronchoesophageal fistulae in an adult.
Iwazawa T; Imazato M; Ohnishi T; Kimura Y; Yano H; Monden T
Jpn J Thorac Cardiovasc Surg; 2004 Aug; 52(8):386-9. PubMed ID: 15384715
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Kato K; Cho BC; Takahashi M; Okada M; Lin CY; Chin K; Kadowaki S; Ahn MJ; Hamamoto Y; Doki Y; Yen CC; Kubota Y; Kim SB; Hsu CH; Holtved E; Xynos I; Kodani M; Kitagawa Y
Lancet Oncol; 2019 Nov; 20(11):1506-1517. PubMed ID: 31582355
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of different treatments for malignant tracheoesophageal/bronchoesophageal fistulae.
Hu Y; Zhao YF; Chen LQ; Zhu ZJ; Liu LX; Wang Y; Kou YL
Dis Esophagus; 2009; 22(6):526-31. PubMed ID: 19302211
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of bronchoesophageal fistula with esophageal and bronchial stenting.
Wang CY; Chou CH; Wang HP; Chen JS; Lee P
J Formos Med Assoc; 2011 Apr; 110(4):270-2. PubMed ID: 21540011
[TBL] [Abstract][Full Text] [Related]
17. IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma.
Kishi S; Minato M; Saijo A; Murakami N; Tamaki M; Matsuura M; Murakami T; Nagai K; Abe H; Nishioka Y; Doi T
Intern Med; 2018 May; 57(9):1259-1263. PubMed ID: 29279511
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of subsequent docetaxel +/- ramucirumab and S-1 after nivolumab for patients with advanced non-small cell lung cancer.
Tamura N; Horinouchi H; Sekine K; Matsumoto Y; Murakami S; Goto Y; Kanda S; Fujiwara Y; Yamamoto N; Ohe Y
Thorac Cancer; 2019 May; 10(5):1141-1148. PubMed ID: 30913364
[TBL] [Abstract][Full Text] [Related]
19. [Docetaxel and Ramucirumab Combination Chemotherapy after Nivolumab Treatment for Pretreated Pulmonary Squamous Cell Carcinoma-A Successful Case].
Kamiyoshihara M; Yazawa T; Igai H; Matsuura N; Ohsawa F; Iwashita H
Gan To Kagaku Ryoho; 2021 Feb; 48(2):211-213. PubMed ID: 33597361
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitor as a Therapeutic Choice for Double Cancer: A Case Series.
Aoki H; Matsumoto N; Takahashi H; Honda M; Kaneko T; Arima S; Ishii T; Mizutani T; Masuzaki R; Nirei K; Yamagami H; Ogawa M; Kanda T; Moriyama M; Miura K
Anticancer Res; 2021 Dec; 41(12):6225-6230. PubMed ID: 34848477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
